AI-Powered Diagnostic Radiogenomics Devices Market Report 2026

The artificial intelligence (AI)-powered diagnostic radiogenomics devices market size has grown rapidly in recent years. It will grow from $0.62 billion in 2025 to $0.74 billion in 2026 at a compound annual growth rate (CAGR) of 19.2%. The growth in the historic period can be attributed to growing prevalence of chronic and complex diseases, rising adoption of advanced diagnostic imaging technologies, increasing investment in precision medicine research initiatives, expansion of genomic sequencing and molecular profiling applications, growing demand for data-driven clinical decision-making solutions.

The artificial intelligence (AI)-powered diagnostic radiogenomics devices market size is expected to see rapid growth in the next few years. It will grow to $1.5 billion by 2030 at a compound annual growth rate (CAGR) of 19.5%. The growth in the forecast period can be attributed to increasing demand for AI-enabled personalized treatment planning solutions, rising adoption of cloud-based radiogenomic data analytics platforms, growing integration of genomics with diagnostic imaging workflows, increasing investment in oncology and neurology precision diagnostics, rising focus on early disease detection and predictive healthcare technologies. Major trends in the forecast period include increasing adoption of multimodal imaging and genomics integration platforms, growing demand for personalized and precision diagnostic solutions, rising use of predictive analytics for disease prognosis and therapy response assessment, increasing implementation of automated radiogenomic data interpretation tools, growing focus on real-time clinical decision support in diagnostic workflows.

The increasing adoption of precision medicine approaches is expected to propel the growth of the AI-powered diagnostic radiogenomics devices market going forward. Precision medicine approaches refer to medical strategies that tailor disease prevention, diagnosis, and treatment based on individual genetic, environmental, and lifestyle variations. The rising adoption of precision medicine is primarily driven by the expanding integration of genomic data into clinical decision-making processes across advanced healthcare systems. AI-powered diagnostic radiogenomics devices support this trend by combining medical imaging data with genomic datasets to enable precise disease profiling, early diagnosis, and personalized treatment planning. For instance, in February 2024, according to a report by the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, more than one-third of new drug approvals by the U. S. Food and Drug Administration were personalized therapies for four consecutive years through 2023. Therefore, the increasing adoption of precision medicine approaches is contributing to and supporting the growth of the AI-powered diagnostic radiogenomics devices market.

Leading companies operating in the AI-powered diagnostic radiogenomics devices market are increasingly focusing on technological advancements such as imaging quality assessment tools to enhance diagnostic accuracy and standardization. An imaging quality assessment tool is a software-based system that uses advanced algorithms to evaluate, standardize, and ensure the reliability of medical imaging data. For example, in June 2025, Quibim, a Spain-based medical imaging technology company, launched AI-QUAL, a solution that applies artificial intelligence to automatically assess prostate magnetic resonance imaging quality, assign standardized scores, and detect artifacts that may compromise diagnostic outcomes. The tool enhances radiology workflows and supports more reliable clinical decision-making by ensuring high-quality imaging data, which is essential for downstream applications such as radiogenomics.

In March 2026, RadNet acquired Gleamer for $270 million. The acquisition is intended to strengthen RadNet’s artificial intelligence capabilities in radiology by incorporating Gleamer’s diagnostic technologies and global software-as-a-service platform across X-ray, mammography, CT, and MRI imaging. This integration is expected to improve imaging workflows related to screening, detection, and diagnostic interpretation for conditions including cancer, musculoskeletal disorders, and neurodegenerative diseases.

Major companies operating in the artificial intelligence (ai)-powered diagnostic radiogenomics devices market are Thermo Fisher Scientific Inc., Siemens Healthineers AG, Philips Healthcare (Koninklijke Philips N. V.), GE HealthCare Technologies Inc., Agilent Technologies Inc., Canon Medical Systems Corporation, Tempus AI Inc., Aidoc Medical Ltd., Owkin Inc., SOPHiA GENETICS SA, Lunit Inc., Synaptive Medical Inc., Median Technologies SA, Perspectum Ltd., Quibim S. L., Seno Medical Instruments Inc., Ultromics Limited, QMENTA Inc., Imbio LLC, Mirada Medical Limited, VUNO Inc., Radiomics. bio Inc., Qlucore AB, CureMetrix Inc.

North America was the largest region in the artificial intelligence (AI)-powered diagnostic radiogenomics devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-powered diagnostic radiogenomics devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the artificial intelligence (AI)-powered diagnostic radiogenomics devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The artificial intelligence (AI)-powered diagnostic radiogenomics devices market consists of sales of radiogenomic data integration platforms, artificial intelligence-based image-genomic correlation software, predictive analytics engines for genotype-phenotype mapping, cloud-enabled radiogenomics processing systems,, genomic annotation and imaging biomarker extraction tools, and interoperable radiology-genomics data management systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.